Sign In
Buy IMTX
$10.21
+0.165 (+1.64%)
At Close: Jun 03, 2026
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
08:00am, Monday, 01'st Jun 2026
Houston, Texas and Tuebingen, Germany , June 1, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-sta
Houston, Texas and Tuebingen , Germany, May 31, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-sta
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
08:00am, Saturday, 30'th May 2026
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer wi
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
09:25am, Tuesday, 12'th May 2026
Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.35 per share a year ago.
Immatics Announces First Quarter 2026 Financial Results and Business Update
07:00am, Tuesday, 12'th May 2026
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company's first commercial launch planned in 2027 Multiple key clini
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
01:01pm, Wednesday, 06'th May 2026
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Houston, Texas and Tuebingen, Germany, April 21, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage progr
Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-st
Individual experimental treatment attempt at Hopp Children's Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR p
SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX
04:45am, Sunday, 05'th Apr 2026
SG Americas Securities LLC acquired a new stake in shares of Immatics N.V. (NASDAQ: IMTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange
Immatics N.V. (NASDAQ:IMTX) Receives $19.00 Average PT from Analysts
01:31am, Friday, 27'th Mar 2026
Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat.com reports. One invest
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot
01:35pm, Monday, 09'th Mar 2026
Immatics (IMTX) remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline. IMTX's valuation reflects high expectations, with the PRAME franchise and
Immatics (NASDAQ:IMTX) Trading Down 5% – Here’s What Happened
04:36am, Sunday, 22'nd Feb 2026
Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s share price traded down 5% on Friday. The stock traded as low as $9.95 and last traded at $9.79. 25,593 shares were traded during trading, a decline of
Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of “Moderate Buy” from Analysts
04:09am, Monday, 02'nd Feb 2026
Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat reports. One in
Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy?
03:38am, Friday, 02'nd Jan 2026
Immatics N.V. (NASDAQ: IMTX - Get Free Report) shot up 3.9% on Wednesday. The stock traded as high as $10.42 and last traded at $10.4630. 130,449 shares traded hands during mid-day trading, a decline
